Drug Farm Announces First-in-Human Dosing of ALPK1 Inhibitor DF-003 in Phase 1 Clinical Trial
Drug Farm
Innovative Therapies Researcher for Infectious and Immune Diseases
▎Reporting by the WuXi AppTec Content Team
On September 19, Drug Farm announced that the first subject in the Phase 1 clinical trial evaluating DF-003 in healthy volunteers has successfully completed dosing.DF-003 was developed through Drug Farm's original IDInVivo+ and MedChem5 platform technologies.ALPK1 Inhibitor Small Molecule Drug in Development, which was approved for clinical use in the U.S. this past July.
ALPK1 is a key target in regulating inflammatory pathways in cardiac and renal pathologyHighly active (Gain-of-function) mutations in ALPK1 can also lead to a rare genetic disorder known as ROSAH syndrome, which causes blindness. Therefore, DF-003 is considered promising for treating hundreds of millions of patients worldwide with heart disease and chronic kidney disease, while providing a precise targeted therapy for ROSAH syndrome.
DF-003 isAn efficient inhibitor under research that can inhibit ALPK1 and the cause of ROSAH patients' illnessALPK1 T237MDriver Mutation。The product demonstrated significant preclinical activity in cardiac and renal animal disease models as well as in the ROSAH transgenic mouse model. Additionally, DF-003 exhibits favorable drug-like properties, including low off-target and drug interaction risks, along with a half-life suitable for once-daily dosing in humans.
"We are very pleased to see that our technological achievements can push the innovative drug DF-003 into the clinical stage," said the co-founder and chief operating officer of Drug Farm.Dr. Xu Cong"It was evaluated that 'DF-003 is a potent, highly selective ALPK1 oral inhibitor with good preclinical efficacy in cardio-renal disease and ROSAH animal disease models.'"
Chief Medical Officer of Drug FarmDr. Jeysen Yogaratnam"The Phase 1 study will evaluate single and multiple ascending doses of DF-003 in healthy volunteers, informing dose selection for Phase 2 clinical trials. We look forward to completing the Phase 1 clinical study and providing a novel treatment option for patients with heart and kidney diseases as well as ROSAH syndrome."
This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Individuals are welcome to share it on their social media feeds. For authorization to repost, please contact us via a message on the "MedView" WeChat official account. For other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
